Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice

The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus

(2015) Volker Vallon   Annual Review of Medicine

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition

(2015) Giulia Ferrannini et al.   DIABETES CARE

A hepatic amino acid/mTOR/S6K-dependent signalling pathway modulates systemic lipid metabolism via neuronal signals

(2015) Kenji Uno et al.   Nature Communications

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

(2014) Masanori Yokono et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

(2014) Steven P Vickers et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function indb/dbmice

(2013) T Nagata et al.   BRITISH JOURNAL OF PHARMACOLOGY

Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus

(2013) L. H. Chen et al.   DIABETES OBESITY & METABOLISM

Chronic mild stress alters circadian expressions of molecular clock genes in the liver

(2012) Kei Takahashi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Hepatic Glucokinase Modulates Obesity Predisposition by Regulating BAT Thermogenesis via Neural Signals

(2012) Sohei Tsukita et al.   Cell Metabolism

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

(2012) Ele Ferrannini et al.   Nature Reviews Endocrinology

Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats

(2012) James J. Devenny et al.   Obesity

Implications of nonshivering thermogenesis for energy balance regulation in humans

(2011) Wouter D. van Marken Lichtenbelt et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

(2011) Atsuo Tahara et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Renal glucose reabsorption inhibitors to treat diabetes

(2011) Clifford J. Bailey   TRENDS IN PHARMACOLOGICAL SCIENCES

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE

Central control of thermogenesis in mammals

(2008) Shaun F. Morrison et al.   EXPERIMENTAL PHYSIOLOGY